CN109182271A - Methods and applications based on organoid method building normal immunological mouse Human gastric cancer xenografts model - Google Patents
Methods and applications based on organoid method building normal immunological mouse Human gastric cancer xenografts model Download PDFInfo
- Publication number
- CN109182271A CN109182271A CN201811109064.XA CN201811109064A CN109182271A CN 109182271 A CN109182271 A CN 109182271A CN 201811109064 A CN201811109064 A CN 201811109064A CN 109182271 A CN109182271 A CN 109182271A
- Authority
- CN
- China
- Prior art keywords
- gastric cancer
- cell
- human gastric
- microcarrier
- mouse
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010017758 gastric cancer Diseases 0.000 title claims abstract description 55
- 208000005718 Stomach Neoplasms Diseases 0.000 title claims abstract description 54
- 201000011549 stomach cancer Diseases 0.000 title claims abstract description 54
- 238000000034 method Methods 0.000 title claims abstract description 34
- 210000002220 organoid Anatomy 0.000 title claims abstract description 27
- 230000001900 immune effect Effects 0.000 title claims abstract description 22
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 59
- 239000003814 drug Substances 0.000 claims abstract description 9
- 238000011740 C57BL/6 mouse Methods 0.000 claims abstract description 7
- 238000012827 research and development Methods 0.000 claims abstract description 5
- 210000004027 cell Anatomy 0.000 claims description 33
- 210000004881 tumor cell Anatomy 0.000 claims description 21
- 239000000725 suspension Substances 0.000 claims description 15
- 238000004113 cell culture Methods 0.000 claims description 9
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 239000007853 buffer solution Substances 0.000 claims description 7
- 238000007920 subcutaneous administration Methods 0.000 claims description 6
- 230000012010 growth Effects 0.000 claims description 5
- 238000001727 in vivo Methods 0.000 claims description 5
- 230000001788 irregular Effects 0.000 claims description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 claims description 4
- 239000002131 composite material Substances 0.000 claims description 4
- 239000012894 fetal calf serum Substances 0.000 claims description 4
- 239000001963 growth medium Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 235000015097 nutrients Nutrition 0.000 claims description 4
- 238000004140 cleaning Methods 0.000 claims description 3
- 238000002513 implantation Methods 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 2
- 210000005056 cell body Anatomy 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 230000005740 tumor formation Effects 0.000 abstract description 10
- 238000010171 animal model Methods 0.000 abstract description 7
- 238000005516 engineering process Methods 0.000 abstract description 7
- 230000036737 immune function Effects 0.000 abstract description 7
- 239000000463 material Substances 0.000 abstract description 5
- 150000001875 compounds Chemical class 0.000 abstract description 4
- 230000007246 mechanism Effects 0.000 abstract description 4
- 239000003005 anticarcinogenic agent Substances 0.000 abstract description 3
- 238000011161 development Methods 0.000 abstract description 3
- 238000004043 dyeing Methods 0.000 abstract description 3
- 208000035269 cancer or benign tumor Diseases 0.000 abstract description 2
- 238000003364 immunohistochemistry Methods 0.000 abstract description 2
- 238000002054 transplantation Methods 0.000 abstract description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 29
- 238000011081 inoculation Methods 0.000 description 7
- 241000699660 Mus musculus Species 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000011580 nude mouse model Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 3
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000220317 Rosa Species 0.000 description 2
- 238000011579 SCID mouse model Methods 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 102000006277 CDX2 Transcription Factor Human genes 0.000 description 1
- 108010083123 CDX2 Transcription Factor Proteins 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 1
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008004 immune attack Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/02—Breeding vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0068—General culture methods using substrates
- C12N5/0075—General culture methods using substrates using microcarriers
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Environmental Sciences (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Based on the methods and applications of organoid method building normal immunological mouse Human gastric cancer xenografts model, the present invention relates to a kind of medicine animal models for tumour-to be based on organoid method.The present invention for the first time using " organoid " technology i.e.-using microcarrier as base material, compound SGC-7901 cells/MKN-45, which are transplanted, subcutaneously successfully constructs the human gastric cancer mouse transplanting tumor model with normal immunological function in C57BL/6 mouse.The tumor model Tumor formation constructed using the method is good, and tumor formation rate is up to 75%, and transplantable tumor HE dyeing and immunohistochemistry meet human gastric cancer feature.Compared with existing immunodeficient mouse neoplasm transplantation; the model preferably can study and further elucidate tumour occur in immune function normal body, development mechanism, while also providing relatively previous more valuable new animal model for the research and development of anticarcinogen.The present invention is applied to tumor model field.
Description
Technical field
The invention belongs to field of medicaments, are based on " organoid " technology more particularly to a kind of medicine animal model for tumour-,
Using microcarrier (NMC1) construct human gastric cancer normal immunological mice-transplanted tumor model, and establish the model method and they
Application in tumor research, clinical trial, susceptibility detection and other pharmaceutical fields.
Background technique
Tumour is a kind of frequently-occurring disease and common disease for seriously threatening human health, and pathogenesis is not yet illustrated completely, controlled
Therapeutic effect is also unsatisfactory.Existing tumor model research is based primarily upon two kinds, first is that external model, that is, establish two and three dimensions
Tumor model；Second is that establish animal model, mainly human tumour model of nude mice bearing tumor.
For animal model, traditional modeling pattern is that human tumor cells are directly injected into nude mice by subcutaneous, and this method is held
Easily cause the loss of cell, and due to the support of no matrix, intercellular connection is not close, therefore tumor formation rate is all in nude mice
It is not high, needless to say there are in the normal mouse body of immunological rejection.It traces it to its cause, it may be possible to due to ignoring between cell and matrix
Interaction this important link, it is difficult to provide and the similar microenvironment of people's in-vivo tumour.This is thin for reappearing human tumor
Born of the same parents locally stick, invade and DISTANT METASTASES IN has a great impact.Newly it is cited as into research achievement organoid (organoids)
Life science in 2017 is most potential " Annual Technical ", and " organoid " technology is a kind of miniature Three-dimensional cell culture mould
Type is originated from patient's primary tumor, and the technology cultivated in the lab.From organoid formed at the beginning of, to carry out drug
After treatment, these organoids can continue to keep height one with source tumor tissues in histology, molecular level and function
It causes, is well reflected its feature.Tumour organoid is that tumour cell is put into 3D cultivating system, adjusted culture scheme, system
The miniature Three-dimensional cell culture model of the one kind produced, phenotype and genotyping show the height of they and primary tumor
It spends similar.
On the other hand, because nude mice lacks T cell, SCID mouse lacks T cell and B cell simultaneously, and there are immune functions for they
Defect, it is difficult to the relationship of tumorigenesis and transfer and immunity of organism is illustrated, nor research immunotherapy of tumors and exploitation
The most ideal model of new type antineoplastic medicine.The mouse transplanting tumor model of normal immunological function, compensates for because immune deficiency is small
Mouse lacks immunocyte, especially T cell and is unable to accurate simulation body immune system and lacks to the important of immune attack of tumour
Point, thus the more accurately molecular biology of reduction specimens and histological characteristic and tumor microenvironment, it can be preferably
For studying elaboration of tumour mechanism and anti-cancer agent research and development etc..
Summary of the invention
The purpose of the present invention is being based on " organoid " technology, with microcarrier (NMC1) for timbering material, compound human gastric cancer
SGC-7901/MKN-45 cell inoculation subcutaneously constructs in-vivo tumour engineering Human gastric cancer xenografts model in normal immunological mouse,
It is existing using the immunodeficient mouses such as nude mice, SCID mouse to solve current Human gastric cancer xenografts model, it is not easy to raise, price
Valuableness, the not high problem of tumor formation rate；Especially solving immunodeficient mouse Human gastric cancer xenografts model can not reflect that body is exempted from
The problem of epidemic disease system important function played in tumorigenesis process and immunodeficient mouse people's Transplanted tumor model
It is long (generally requiring 4-6 months) there are the tumor formation period, it is difficult to solve the clinical susceptibility demand for urgently needing drug therapy patient.Cause
This establishes novel human gastric cancer normal immunological mice-transplanted tumor model and has great importance.
Normal immunological mouse Human gastric cancer xenografts model building method based on organoid method of the invention, it be according to
What following steps carried out:
1) acquisition of human gastric cancer tumour cell:
After taking human gastric cancer tumour cell SGC-7901/MKN-45 to recover, it is complete that the DMEM containing 10% fetal calf serum is added
Full nutrient solution is 37 DEG C, 5%CO in temperature2It is cultivated in incubator, changes liquid after 24~48 hours, continue to cultivate, passed on 3-4 times；
2) three-dimensional nodule cell culture model is established in organoid method:
After microcarrier is impregnated 48h in the alcohol that volumn concentration is 75%, cleaned 5 times with 1 × PBS buffer solution,
24~48h is incubated in DMEM culture medium；
The human gastric cancer tumour cell SGC-7901/MKN-45 of exponential phase of growth after taking step 1) to pass on, if trypan blue counts
Viable count > 95% then adjusts human gastric cancer tumour cell SGC-7901/MKN-45 concentration to 2 × 107/mL；By people adjusted
Gastric cancer tumor cell SGC-7901/MKN-45 suspension is mixed with the microcarrier being incubated for, and obtains cell-microcarrier complex；By its
It is 37 DEG C, 5%CO in temperature224~48h is cultivated in incubator；
3) building of Mouse Gastric Cancer transplantable tumor:
With 1 × PBS buffer solution cleaning step 2) cell-microcarrier complex for being incubated for cleans 4 times, then it is slow with 1 × PBS
Fliud flushing is resuspended cell and adjusts cell concentration to 2 × 107/ mL adjusts microcarrier concentration to 200ug~350ug/mL, obtains cell-
Microcarrier suspension is placed in spare on ice；Cell-microcarrier suspension is injected in 6-8 weeks C57BL/6 mouse, in vivo
After implantation 20-30 days, i.e., normal immunological mouse Human gastric cancer xenografts model is completed in building.
The present invention include it is following the utility model has the advantages that
Invention introduces tumour 3 D culture techniques, are based on " organoid " technology, are established using 3D material for carrier
Three-dimensional cell culture model lays the foundation for the further research of tumour.
The present invention utilize " organoid " dimensional culture technology building vivo tumor model mainly by tumor cell inoculation in
On microcarrier (NMC1) timbering material, then directly tumour will be constructed in cell-composite body injection normal immunological Mice Body
Model.
The present invention utilizes " organoid " culture technique, with microcarrier (NMC1) for base material, compound gastric carcinoma cells
SGC-7901/MKN-45 is inoculated in C57BL/6 mouse and subcutaneously successfully constructs the human gastric cancer mouse shifting with normal immunological function
Plant tumor model.Compared with existing immunodeficient mouse neoplasm transplantation, which can preferably be studied and further
Illustrate tumour occur in immune function normal body, development mechanism, while also for the research and development of anticarcinogen provide it is relatively previous more
Valuable new animal model.
SGC-7901 cells/MKN-45- microcarrier complex is seeded to C57BL/6 mouse by the present invention, is connect certainly
Start after kind to the 10th day, mouse ingests normally, and activity situation is good, and the 10th day starts, and mouse activity is slightly reduced, but appetite, hair
Hair, weight no significant difference.8~10d, that is, accessible tumour after inoculation, tumor formation rate are 75% (15/20), transplantable tumor shape
State is relatively regular, mostly round or ellipse, and color is based on canescence or bois de rose.
Detailed description of the invention
The gross examination of skeletal muscle figure of Fig. 1 mice with tumor and transplantable tumor；Wherein, A: figure, B: figure, C: figure；
Fig. 2 is successfully established SGC-7901/MKN-45 three-dimensional cell cultivation system figure in vitro；Wherein, A:SGC-7901/MKN-
45 cell two dimension cultures × 100 figures；The figure of B:NMC1 × 100；C: figure for 24 hours × 100 is co-cultured；D: it co-cultures for 24 hours (DAPI) × 100
Figure；
Fig. 3 Human gastric cancer xenografts HE colored graph；Wherein, A: × 100HE colored graph；B: × 100HE colored graph；C: ×
200HE colored graph；D: × 400HE colored graph；
Fig. 4 Human gastric cancer xenografts immunohistochemical staining figure；Wherein, the colored graph of A:CA199 × 200；B:CEA × 200
Colored graph；C:CDX-2 colored graph.
Specific embodiment
Specific embodiment 1: the normal immunological mouse Human gastric cancer xenografts mould based on organoid method of present embodiment
Type construction method, it is followed the steps below:
1) acquisition of human gastric cancer tumour cell:
After taking human gastric cancer tumour cell SGC-7901/MKN-45 to recover, it is complete that the DMEM containing 10% fetal calf serum is added
Full nutrient solution is 37 DEG C, 5%CO in temperature2It is cultivated in incubator, changes liquid after 24~48 hours, continue to cultivate, passed on 3-4 times；
2) three-dimensional nodule cell culture model is established in organoid method:
After microcarrier is impregnated 48h in the alcohol that volumn concentration is 75%, cleaned 5 times with 1 × PBS buffer solution,
24~48h is incubated in DMEM culture medium；
The human gastric cancer tumour cell SGC-7901/MKN-45 of exponential phase of growth after taking step 1) to pass on, if trypan blue counts
Viable count > 95% then adjusts human gastric cancer tumour cell SGC-7901/MKN-45 concentration to 2 × 107/mL；By people adjusted
Gastric cancer tumor cell SGC-7901/MKN-45 suspension is mixed with the microcarrier being incubated for, and obtains cell-microcarrier complex；By its
It is 37 DEG C, 5%CO in temperature224~48h is cultivated in incubator；
3) building of Mouse Gastric Cancer transplantable tumor:
With 1 × PBS buffer solution cleaning step 2) cell-microcarrier complex for being incubated for cleans 4 times, then it is slow with 1 × PBS
Fliud flushing is resuspended cell and adjusts cell concentration to 2 × 107/ mL adjusts microcarrier concentration to 200ug~350ug/mL, obtains cell-
Microcarrier suspension is placed in spare on ice；Cell-microcarrier suspension is injected in 6-8 weeks C57BL/6 mouse, in vivo
After implantation 20-30 days, i.e., normal immunological mouse Human gastric cancer xenografts model is completed in building.
Specific embodiment 2: the present embodiment is different from the first embodiment in that: human gastric cancer tumour in step 2)
The volume ratio of cell SGC-7901/MKN-45 suspension and the microcarrier being incubated for is 1:3-5；It is 1:4 compared with the figure of merit.It is other with it is specific
Embodiment one is identical.
Specific embodiment 3: the present embodiment is different from the first embodiment in that: it cultivates in step 1) to cell
It more than length to 90% density is passed on, is changed the liquid once within every two days.It is other same as the specific embodiment one.
Specific embodiment 4: the present embodiment is different from the first embodiment in that: in step 2) temperature be 37
DEG C, 5%CO224~48h is cultivated in incubator, is carried out in next step after microscopic observation cell reaches saturation state in microcarrier
Operation.It is other same as the specific embodiment one.
Specific embodiment 5: the present embodiment is different from the first embodiment in that: cell-microcarrier in step 3)
The position that suspension injects mouse is subcutaneous under right axillary, every injection 100uL.It is other same as the specific embodiment one.
Specific embodiment 6: the present embodiment is different from the first embodiment in that: the microcarrier is by can
Positive electrification organic composite polymer composition, is in the poroid bar rope sample of multilayer, is cross-linked with each other and curls into " labyrinth " of sufficient space
Sample irregular structure.It is other same as the specific embodiment one.
The microcarrier pore size, positive surface charge density, carrier granular size can be adjusted by chemical synthesis, be pure to have
Machine compound, it is not easy to pollute, it is free from foreign meter, have the characteristics that low immunogenicity, simultaneous the melting property of biology and metabolizability, can be cell
Growth provides stable microenvironment.Enough spaces solve cell growing nutrient and metabolic waste density unevenness inside microcarrier
The problem of, simultaneously as microcarrier " labyrinth " the sample irregular structure can play barrier action (in the short time), in certain journey
Stop immunocyte to the direct killing of tumour cell on degree.In addition, after being modified with SDF-1 α and VEGF microcarrier, it can
Accelerate vascularization, induction of vascular is grown into, and provides nutritional blood supply for the fast-growth of tumour.
It should be noted that microcarrier is named as NMC1 by the present invention, all NMC1 occurred in the present invention refer to this implementation
Microcarrier defined by mode.
Specific embodiment 7: the normal immunological mouse Human gastric cancer xenografts that present embodiment utilizes embodiment one to construct
Model application, it is researched and developed for gastric cancer medicament.
Specific embodiment 8: present embodiment is unlike specific embodiment six: it is screened in anti-gastric cancer medicament
In clinical application.It is other identical as specific embodiment six.
The content of present invention is not limited only to the content of the respective embodiments described above, the group of one of them or several specific embodiments
The purpose of invention also may be implemented in contract sample.
Beneficial effects of the present invention are verified by following instance:
Embodiment 1
The model method of the present embodiment is as follows:
Step 1: the culture of stomach cancer cell
SGC-7901 cells/MKN-45 purchase is trained in Shanghai Cell Bank of the Chinese Academy of Sciences using DMEM culture medium
It supports, adds 10% fetal calf serum；It more than cell length to 90% density is passed on, is changed the liquid once within every two days；Cell be placed in 37 DEG C,
5%CO2It is cultivated in incubator.
Step 2: the preparation of liquid phase microcarrier
Microcarrier NMC1 is soaked in 75% alcohol 48h, 1 × phosphate buffer (PBS) cleans 4 times, cultivates in DMEM
It is spare that 24-48h is incubated in base.
Step 3: the foundation of three-dimensional nodule cell culture model
Take the SGC-7901/MKN-45 cell of exponential phase of growth, trypan blue living cell counting number > 95%, by SGC-7901/
MKN-45 cell suspension mixes (volume ratio 1:4) with the microcarrier (NMC1) being incubated for, and is made containing 2 × 107A cell/mL's is thin
Born of the same parents-microcarrier suspension；In 37 DEG C, 5%CO2It is cultivated 24-48 hours in incubator, reaches cell in microcarrier (NMC1)
It is saturated shape.
Step 4: the building of Mouse Gastric Cancer transplantable tumor
Cell-microcarrier complex 3 times be incubated for are cleaned with 1 × PBS liquid, then the micro- load of cell-is resuspended with 1 × PBS liquid
(cell concentration is 2 × 10 to composite7/ mL, microcarrier concentration 250/mL), by the made cell-microcarrier got ready
(NMC1) suspension is placed on spare on ice；Cell-microcarrier complex is then injected in 6-8 weeks big C57BL/6 mouse,
Position is subcutaneous under right axillary, every 100uL, and the subcutaneous hillock that formed indicates to be inoculated with successfully, and et al. Ke 20-30 days, building was just
Often immune mouse Human gastric cancer xenografts model.
Step 5: mouse tumor formation situation
Observe the ordinary circumstances such as spirit, diet, activity, the stool and urine of mouse after transplanting daily, at transplanting subcutaneously whether at
Tumor.From from inoculation to inoculation position occur it is tangible to solid mass when for incubation period, find to start after tumor formation daily
With the maximum gauge (Dmax) and minimum diameter (Dmin) of vernier caliper measurement tumour, by formula V=1/2 × Dmax × (Dmin)
2 calculate gross tumor volume.
Step 6: pathological examination
Tumor growth 20-30 days, cervical dislocation put to death mouse, took out complete tumors, and 10% neutral formalin is fixed, and made
Make paraffin section, Hematoxylin-eosin (HE) dyeing, immunohistochemistry detects the expression of CA199, CEA, COX-2 albumen.
Mouse ordinary circumstance and growth of transplanted human situation
To the 10th day since after inoculation, mouse ingests normally, and activity situation is good, and the 10th day starts, and mouse activity slightly subtracts
It is few, but appetite, hair, weight no significant difference.8~10d, that is, accessible tumour after inoculation, tumor formation rate are 75% (15/20
Only), transplantable tumor form is relatively regular, mostly round or ellipse, and color is based on canescence or bois de rose.
SGC-7901/MKN-45 three-dimensional cell cultivation system is established in vitro
Two-dimensional environment observation SGC-7901/MKN-45 cell is adherent, is in irregular shape；Microcarrier (NMC1) is under the microscope
Irregular bulk or long fusiform, quality are loose；SGC-7901/MKN-45 cell and microcarrier (NMC1) are co-cultured 24-48 hours
Afterwards it can be seen that SGC-7901/MKN-45 cell can be very good to be attached on microcarrier (NMC1), reach saturation state.
Oncological pathology
HE dyeing: the big dye deeply of transplanting tumor tissue visible a large amount of cores under light microscopic, not of uniform size, heteromorphism is obvious, mixed and disorderly row
The cell of column, and grown to skin, fat, musculature infiltration；With necrosis, it is located at center of tumor；That is not yet removed lacks
Perhaps microcarrier (NMC1) is wrapped to form granuloma；New capillary vessel is abundant in tumor tissue, and multidigit is in borderline tumor.
Immunohistochemical staining: CA199, CEA, COX-2 are mainly expressed in cancer cell membrane and cytoplasm, the results show that CA199,
CEA, COX-2 are positive expression, further confirm that atypia cell is human tumor cells.
By above-mentioned experiment it is found that the model that the present embodiment is established is that xenogenesis plant shifting has the function of normal immunological mouse tumor mould
Type has method easy, and the period is short, is easy to raise, the high advantage of tumor formation rate.The model can be studied preferably and further be explained
Bright tumour occurs in immune function normal body, development mechanism, clinical trial, the detection of anticancer susceptibility, while being also anticarcinogen
Research and development provide relatively previous more valuable novel animal model.
Claims (8)
1. based on organoid method building normal immunological mouse Human gastric cancer xenografts model method, it is characterised in that it be according to
What following steps carried out:
1) acquisition of human gastric cancer tumour cell:
After taking human gastric cancer tumour cell SGC-7901/MKN-45 to recover, the DMEM containing 10% fetal calf serum is added and trains completely
Nutrient solution is 37 DEG C, 5%CO in temperature2It is cultivated in incubator, changes liquid after 24~48 hours, continue to cultivate, passed on 3-4 times；
2) three-dimensional nodule cell culture model is established in organoid method:
After microcarrier is impregnated 48h in the alcohol that volumn concentration is 75%, cleaned 5 times with 1 × PBS buffer solution, in
24~48h is incubated in DMEM culture medium；
The human gastric cancer tumour cell SGC-7901/MKN-45 of exponential phase of growth after taking step 1) to pass on, lives carefully if trypan blue counts
Born of the same parents' number > 95% then adjusts human gastric cancer tumour cell SGC-7901/MKN-45 concentration to 2 × 107/mL；By human gastric cancer adjusted
Tumour cell SGC-7901/MKN-45 suspension is mixed with the microcarrier being incubated for, and obtains cell-microcarrier complex；By it in temperature
Degree is 37 DEG C, 5%CO224~48h is cultivated in incubator；
3) building of Mouse Gastric Cancer transplantable tumor:
With 1 × PBS buffer solution cleaning step 2) cell-microcarrier complex for being incubated for cleans 4 times, then with 1 × PBS buffer solution
Cell is resuspended and adjusts cell concentration to 2 × 107/ mL adjusts microcarrier concentration to 200ug~350ug/mL, obtains the micro- load of cell-
Body suspension is placed in spare on ice；The C57BL/6 mouse that cell-microcarrier suspension is injected in 6-8 weeks is subcutaneous, in vivo
After implantation 20-30 days, i.e., normal immunological mouse Human gastric cancer xenografts model is completed in building.
2. the side according to claim 1 based on organoid method building normal immunological mouse Human gastric cancer xenografts model
Method, it is characterised in that the microcarrier is made of positive electrochemical organic composite polymer, is in the poroid bar rope sample of multilayer, is mutually handed over
Connection curls into " labyrinth " sample irregular structure of sufficient space.
3. the side according to claim 1 based on organoid method building normal immunological mouse Human gastric cancer xenografts model
Method, it is characterised in that the volume of human gastric cancer tumour cell SGC-7901/MKN-45 suspension and the microcarrier being incubated in step 2)
Than for 1:3-5.
4. the side according to claim 1 based on organoid method building normal immunological mouse Human gastric cancer xenografts model
Method, it is characterised in that more than culture to cell length to 90% density passed on, changed the liquid once in step 1) for every two days.
5. the side according to claim 1 based on organoid method building normal immunological mouse Human gastric cancer xenografts model
Method, it is characterised in that in step 2) temperature be 37 DEG C, 5%CO224~48h is cultivated in incubator, is existed in microscopic observation cell
Next step operation is carried out after reaching saturation state in microcarrier.
6. the side according to claim 1 based on organoid method building normal immunological mouse Human gastric cancer xenografts model
Method, it is characterised in that cell-microcarrier suspension injection mouse position is subcutaneous under right axillary, every injection in step 3)
100uL。
7. the normal immunological mouse Human gastric cancer xenografts model application that claim 1 constructs, it is characterised in that it is for gastric cancer
Medicament research and development.
8. application according to claim 7, it is characterised in that it anti-gastric cancer medicament screening in clinical application.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811109064.XA CN109182271A (en) | 2018-09-21 | 2018-09-21 | Methods and applications based on organoid method building normal immunological mouse Human gastric cancer xenografts model |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811109064.XA CN109182271A (en) | 2018-09-21 | 2018-09-21 | Methods and applications based on organoid method building normal immunological mouse Human gastric cancer xenografts model |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109182271A true CN109182271A (en) | 2019-01-11 |
Family
ID=64909562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811109064.XA Pending CN109182271A (en) | 2018-09-21 | 2018-09-21 | Methods and applications based on organoid method building normal immunological mouse Human gastric cancer xenografts model |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109182271A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110338148A (en) * | 2019-06-21 | 2019-10-18 | 核工业总医院 | Method and application based on radiation Remote effects joint bystander cell control peritonaeum transfer |
| CN112575069A (en) * | 2020-11-17 | 2021-03-30 | 哈尔滨医科大学 | Tumor evolution regulation and control model based on subclone level sensitive drug screening and establishment method thereof |
| CN114304065A (en) * | 2021-12-31 | 2022-04-12 | 江苏大学 | Construction and application of animal model for treating gastric cancer by blocking IL-8 and combining anti-PD-1 antibody |
| CN114480250A (en) * | 2020-11-12 | 2022-05-13 | 四川大学华西医院 | Method for constructing in-situ primary gastric cancer animal model |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102125698A (en) * | 2010-11-29 | 2011-07-20 | 昆明理工大学 | Method for establishing mouse transplanting tumor model with normal immunologic function |
| KR20140133399A (en) * | 2013-05-07 | 2014-11-19 | 재단법인 아산사회복지재단 | Methods for cultivation of patient derived primary cultured turmor cell (PCC) and patient-derived tumor xenograft (PDX) animal model produced by using PCC |
| CN107137424A (en) * | 2017-05-15 | 2017-09-08 | 广州领晟医疗科技有限公司 | A kind of method that utilization normal mouse sets up the animal model of HER2 positive tumors |
-
2018
- 2018-09-21 CN CN201811109064.XA patent/CN109182271A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102125698A (en) * | 2010-11-29 | 2011-07-20 | 昆明理工大学 | Method for establishing mouse transplanting tumor model with normal immunologic function |
| KR20140133399A (en) * | 2013-05-07 | 2014-11-19 | 재단법인 아산사회복지재단 | Methods for cultivation of patient derived primary cultured turmor cell (PCC) and patient-derived tumor xenograft (PDX) animal model produced by using PCC |
| CN107137424A (en) * | 2017-05-15 | 2017-09-08 | 广州领晟医疗科技有限公司 | A kind of method that utilization normal mouse sets up the animal model of HER2 positive tumors |
Non-Patent Citations (1)
| Title |
|---|
| 毕研贞等: "基于microcarrier 6构建正常免疫小鼠人胃癌移植模型", 《中国肿瘤临床》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110338148A (en) * | 2019-06-21 | 2019-10-18 | 核工业总医院 | Method and application based on radiation Remote effects joint bystander cell control peritonaeum transfer |
| CN114480250A (en) * | 2020-11-12 | 2022-05-13 | 四川大学华西医院 | Method for constructing in-situ primary gastric cancer animal model |
| CN114480250B (en) * | 2020-11-12 | 2023-09-08 | 四川大学华西医院 | Method for constructing in-situ primary gastric cancer animal model |
| CN112575069A (en) * | 2020-11-17 | 2021-03-30 | 哈尔滨医科大学 | Tumor evolution regulation and control model based on subclone level sensitive drug screening and establishment method thereof |
| CN114304065A (en) * | 2021-12-31 | 2022-04-12 | 江苏大学 | Construction and application of animal model for treating gastric cancer by blocking IL-8 and combining anti-PD-1 antibody |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109182271A (en) | Methods and applications based on organoid method building normal immunological mouse Human gastric cancer xenografts model | |
| Tzatzalos et al. | Engineered heart tissues and induced pluripotent stem cells: macro-and microstructures for disease modeling, drug screening, and translational studies | |
| CN104403923B (en) | Three-dimensional tissue's organ culture model and high throughput automated stereo-picture analysis platform thereof and application thereof | |
| CN102858380B (en) | Islet cells sheet, manufacture method and Application way thereof | |
| CN103212071B (en) | Stem cell fusion model of carcinogenesis | |
| CN109392843A (en) | Oophoroma Transplanted tumor model and application are constructed based on organoid method | |
| Ye et al. | Organoids to study immune functions, immunological diseases and immunotherapy | |
| CN102399693B (en) | Simulation three-dimensional cell cultivation device and cultivation method | |
| CN106574242A (en) | Single cell-derived organoids | |
| Xie et al. | Organoid culture of isolated cells from patient-derived tissues with colorectal cancer | |
| CN110475860A (en) | Use the dimensional culture of the primary cancer cell of tumor tissues | |
| Zhao et al. | In vivo generation of thick, vascularized hepatic tissue from collagen hydrogel-based hepatic units | |
| CN100540657C (en) | Endotheliocyte derived from primate embryonic stem cells | |
| Nguyen et al. | Developing liver organoids from induced pluripotent stem cells (iPSCs): An alternative source of organoid generation for liver cancer research | |
| US20210047622A1 (en) | Method for obtaining an animal model from conditionally reprogrammed cells and use of the animal model for screeing anti-tumor drugs | |
| WO2019182326A1 (en) | Method and system for 3d cell culture and use thereof | |
| CN107217039A (en) | Tumor tissues 3D cultural methods and nutrient solution | |
| Van Zijl et al. | Hepatospheres: Three dimensional cell cultures resemble physiological conditions of the liver | |
| CN102250840B (en) | Human pancreatic cancer cell line and its application | |
| CN109182272A (en) | The construction method of the liver cancer normal immunological mice-transplanted tumor model in the patient source based on organoid method and its application | |
| Ralphe et al. | 3D engineered cardiac tissue models of human heart disease: learning more from our mice | |
| Khoon | Experimental models of bone metastasis: opportunities for the study of cancer dormancy | |
| Yang et al. | Progress in the application of organoids to breast cancer research | |
| CN102329775B (en) | A kind of human pancreatic cancer cell to gemcitabine resistance and application thereof | |
| CN114717190A (en) | Human breast malignant phylliform tumor cell line BPT0713 and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190111 |